Log in to save to my catalogue

Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in prev...

Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in prev...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1873604134

Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial

About this item

Full title

Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial

Publisher

Berlin/Heidelberg: Springer Berlin Heidelberg

Journal title

Annals of hematology, 2017-04, Vol.96 (4), p.639-646

Language

English

Formats

Publication information

Publisher

Berlin/Heidelberg: Springer Berlin Heidelberg

More information

Scope and Contents

Contents

Fludarabine combinations are very affective in follicular lymphoma (FL) with high rates of complete response and prolonged survival. However, late toxicities could be a concern. The aim of the present study was to analyze the long-term impact on survival, relapse and late toxicities of a trial of treatment with fludarabine, mitoxantrone and cycloph...

Alternative Titles

Full title

Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_1873604134

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1873604134

Other Identifiers

ISSN

0939-5555

E-ISSN

1432-0584

DOI

10.1007/s00277-017-2920-2

How to access this item